A promising treatment, retatrutide, is creating considerable anticipation within the Australian weight management community. Designed by Lilly , this dual GIP and GLP-1 agonist appears to deliver more impressive benefits than current therapies. Initial scientific research have shown remarkable diminutions in body fat , raising the potential for a d